Home > Insider Trading > Filing (0000880771-17-000032)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
880771	Sciclone Pharmaceuticals Inc	SCLN	Pharmaceutical Preparations (2834)	943116852

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1363213	Friedhelm Blobel	950 Tower Lane, Suite 900 Foster City CA 94404	President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-03-06	3,087	$3.55	90,613	No	4	M	Direct
Common Stock	Disposition	2017-03-06	3,087	$10.30	87,526	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2017-03-06	3,087	$0.00	3,087	$3.55
Common Stock	Restricted Stock Unit	Acquisiton	2017-03-08	20,000	$0.00	20,000	$0.00
Common Stock	Incentive Stock Option (right to buy)	Acquisiton	2017-03-08	10,843	$0.00	10,843	$9.65
Common Stock	Non-Qualified Stock Option (right to buy)	Acquisiton	2017-03-08	129,157	$0.00	129,157	$9.65

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
290,400	2020-03-05	No	4	M	Direct
345,000	2027-03-08	No	4	A	Direct
10,843	2027-03-08	No	4	A	Direct
129,157	2027-03-08	No	4	A	Direct

Footnotes

The reported sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2016.
Granted under the Issuer's 2005 Equity Incentive Plan.
25% of each shares vest one year from the date of grant, of March 5, 2010, and 2.0833% vests each month thereafter, provided that Reporting Person continues to be employed by the Issuer.
Granted under the Issuer's 2015 Equity Incentive Plan.
Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
Vesting for such RSUs will occur 25% on March 8, 2018, 25% on March 8, 2019, 25% on March 8, 2020, and 25% on March 8, 2021, contingent upon the executive's continued employment.
25% of such shares vest from one year from the date of grant and 2.0833% vests each month thereafter, provided that the Reporting Person continues to be employed by the Issuer.